Genetic Alteration of a Bispecific Ligand-Directed Toxin Targeting Human CD19 and CD22 Receptors Resulting in Improved Efficacy Against Systemic B Cell Malignancy

Leukemia Research - United Kingdom
doi 10.1016/j.leukres.2009.02.006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Heterogeneity of Surface CD19 and CD22 Expression in B Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2018English

Immunotoxins Against CD19 and CD22 Are Effective in Killing Precursor-B Acute Lymphoblastic Leukemia Cells in Vitro

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

Epratuzumab Targeting of CD22 Affects Adhesion Molecule Expression and Migration of B-Cells in Systemic Lupus Erythematosus

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2010English

CD19 and CD22 Regulate a B Lymphocyte Signal Transduction Pathway That Contributes to Autoimmunity.

Keio Journal of Medicine
Medicine
2000English

A Bispecific EpCAM/CD133-targeted Toxin Is Effective Against Carcinoma

Targeted Oncology
Cancer ResearchOncologyPharmacology
2013English

Ligand Directed Signaling Differences Between Rodent and Human Κ-Opioid Receptors

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2012English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2015English

A Sensitivity Scale for Targeting T Cells With Chimeric Antigen Receptors (CARs) and Bispecific T-Cell Engagers (BiTEs)

OncoImmunology
OncologyAllergyImmunology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy